

HEMOSTASIS OF PATIENTS WITH NON-HODGKIN LYMPHOMA AND ANTICARDIOLIPINIC ANTIBODIES

Authors: Sanda Buruiană¹, Minodora Mazur², Maria Robu¹, Victor Tomacinschii¹, Lucia Mazur-Nicorici³

Affiliations: 1.Discipline of hematology, Nicolae Testemitanu SUMPh; 2.Discipline of internal medicine-semiology, Nicolae Testemitanu SUMPh; 3.Discipline of cardiology, Nicolae Testemitanu SUMPh

Background Anticardiolipin antibodies are autoantibodies that erroneously recognize cardiolipins on the outside of cell membranes, causing hemostasis disorders, which affect the therapeutic conduct, effectiveness of treatment and quality of life of patients with malignant lymphoma.

Purpose

Identification of hemostasis changes in primary patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL)

Material and methods

The study included 83 newly patients (men-34, women-49) with a mean age of 63.2 years, with NHL, investigated complex, by research of lupus anticoagulant (LA) by Turbidimetry; aCL antibodies, antiβ2glycoprotein I IgG, IgM by ELISA method. Hemostasis disorders were evaluated according to the morphological type of NHL, stage, tumor size.




Figure 1. Incidence of anticardiolipin antibodies in patients with non-Hodgkin's lymphoma.

Results

aCL were detected in 10 (12%) patients with advanced stage B cell NHL in 60%, mean age 52.8 years. LA was present in 80% of cases, unlike aCL IgG antibodies and 10% IgG antiβ2glycoprotein I. Hemostasis disorders were found in 6 (60%) patients: thrombosis-at 4 (40%) with mantle cell lymphoma, small lymphocytic lymphoma, lymphoblastic NHL in 75% local stage (I and II), but with a large tumor component (> 11 cm), and hemorrhage at 2 (20%) with stage IV small lymphocyte lymphoma, in which immune thrombocytopenia developed.

Evaluation criterias	Thrombosis	Bleedings
Aggressive NHL (%)	75	-
Indolent NHL (%)	25	100
Mean age (years)	50.25	54
Stages I-II (%)	75	-
Stages III-IV (%)	25	100
Symptoms of general intoxication:		
A (absent) (%)	75	100
B (present) (%)	25	-
Tumor size (cm)	11-12	5-7

Table 1. Peculiarities of hemostasis disorders in patients with non-Hodgkin's lymphoma and anticardiolipin antibodies.

Conclusions

The presence of lupus anticoagulant, advanced age, generalized stage, and large tumor size are risk factors for the development of hemostasis changes in NHL patients, especially thromboembolic events.




Figure 2. Incidence of hemostasis disturbances in patients with non-Hodgkin's lymphoma and anticardiolipin antibodies.